An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status:
No longer available
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide Decitabine to patients with Myelodysplastic syndrome
(MDS) of all FAB (French-American-British) subtypes and Intermediate-1, Intermediate-2, and
High-Risk International Prognostic Scoring System groups, including both previously treated
and untreated patients.